| FTH1 | |
|---|---|
| Full Name | Ferritin Heavy Chain 1 |
| Gene Symbol | FTH1 |
| Chromosomal Location | 19q13.33 |
| NCBI Gene ID | 2495 |
| OMIM ID | 134790 |
| Ensembl ID | ENSG00000196950 |
| UniProt ID | P02794 |
| Protein Family | Ferritin heavy chain subunit |
| Associated Diseases | Neuroferritinopathy, Alzheimer's Disease, Parkinson's Disease, NBIA, ALS |
FTH1 encodes the ferritin heavy chain 1 (FTH1), the catalytic subunit of the ferritin protein complex. While FTL (ferritin light chain) provides structural stability and iron nucleation, FTH1 contains the critical ferroxidase center that catalyzes the conversion of toxic Fe²⁺ (ferrous iron) to Fe³⁺ (ferric iron) for safe storage within the ferritin shell[1]. This enzymatic activity is essential for cellular protection against iron-mediated oxidative damage.
The ferritin complex is composed of 24 subunits (a heteropolymer of heavy and light chains) capable of storing up to 4,500 iron atoms. FTH1 is ubiquitously expressed and is particularly important in the brain, where iron dysregulation is a hallmark of multiple neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[2].
This comprehensive overview addresses the structure, function, and disease associations of FTH1, with particular emphasis on its emerging role in neurodegeneration and therapeutic implications.
The FTH1 gene is located on chromosome 19q13.33, in close proximity to FTL. This genomic organization reflects the evolutionary relationship between the two ferritin subunits.
Key genomic features:
FTH1 combines with FTL to form the functional ferritin heteropolymer:
Structural features[1:1]:
FTH1 plays a central role in cellular iron homeostasis:
Iron sequestration:
Ferroxidase reaction:
Ferritin serves as a crucial antioxidant buffer:
The autophagic degradation of ferritin, termed ferritinophagy, is regulated by NCOA4:
FTH1 is implicated in AD pathogenesis through iron dysregulation[6]:
Amyloid-iron relationship:
Therapeutic implications:
FTH1 plays critical roles in PD pathogenesis[7][8]:
Dopaminergic neuron vulnerability:
Alpha-synuclein interaction:
Iron accumulation is observed in ALS, with FTH1 potentially involved[9]:
While FTL mutations cause neuroferritinopathy, FTH1 is also relevant to NBIA disorders:
FTH1 is expressed throughout the brain, with highest levels in iron-rich regions[10]:
| Brain Region | Expression Level | Cell Types |
|---|---|---|
| Substantia nigra | Very high | Dopaminergic neurons |
| Basal ganglia | Very high | Neurons, glia |
| Cerebellum | High | Purkinje cells |
| Cerebral cortex | Moderate | Pyramidal neurons |
| Hippocampus | Moderate | CA neurons |
Management of ferritin-related neurodegeneration includes[11]:
Iron chelation therapy:
| Drug | Mechanism | Status |
|---|---|---|
| Deferoxamine | Iron chelation | Clinical use |
| Deferasirox | Oral iron chelation | Clinical use |
| Deferiprone | Brain-penetrant | Research |
Antioxidant approaches:
Ferritin modulation[12]:
FTH1 encodes ferritin heavy chain 1, the catalytic subunit of ferritin essential for iron storage and cellular protection against oxidative damage. Through its ferroxidase activity, FTH1 converts toxic Fe²⁺ to Fe³⁺ for safe storage within the ferritin shell, preventing iron-mediated ROS generation.
Beyond its fundamental role in iron homeostasis, FTH1 is increasingly recognized as an important factor in common neurodegenerative diseases. Iron dysregulation, altered ferritin expression, and impaired ferritinophagy all contribute to disease pathogenesis in AD, PD, and ALS.
Therapeutic strategies targeting FTH1 and iron homeostasis include iron chelation, antioxidant therapy, and emerging approaches targeting ferritinophagy. Understanding FTH1 function in neurodegeneration continues to inform therapeutic development.
FTH1 expression is tightly regulated at the translational level through Iron Response Elements (IREs)[13]:
IRE-mediated regulation:
Cellular iron sensing:
The ferroxidase center in FTH1 catalyzes iron oxidation:
Reaction mechanism:
Kinetic parameters:
FTH1 and ferritin have significant biomarker potential[8:1]:
| Sample | Biomarker | Utility |
|---|---|---|
| CSF | Ferritin levels | Iron dysregulation in brain |
| Serum | Ferritin | Systemic inflammation/iron status |
| MRI | QSM | Brain iron accumulation |
| Blood | FTH1 mRNA | Disease progression |
FTH1 polymorphisms have been studied in neurodegenerative diseases:
FTH1 interacts with multiple cellular proteins:
FTH1 is involved in multiple pathways:
FTH1 is highly conserved across species:
| Species | Identity | Notes |
|---|---|---|
| Human | Reference | Full function |
| Mouse | 98% | Single AA difference |
| Zebrafish | 85% | Functional |
| Drosophila | 75% | Single ferritin gene |
| C. elegans | 70% | Different regulation |
The ferritin gene family includes:
FTH1 is highly expressed in dopaminergic neurons:
FTH1 supports cognitive function:
FTH1 in motor control regions:
The 24-subunit ferritin shell assembles from FTH1 and FTL:
Assembly process:
Functional implications:
FTH1 represents a critical node in cellular iron homeostasis with profound implications for neurodegeneration. Its ferroxidase activity, expression pattern, and disease associations make it an important therapeutic target. Ongoing research continues to reveal new aspects of FTH1 function and potential intervention points for neurodegenerative diseases.
Levi S, et al. Ferritin: the ubiquitous protein. Cell and Tissue Research. 2014. ↩︎ ↩︎
Ward RJ, Zucca FA. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurology. 2014. ↩︎
Yang H, et al. Ferritinophagy in neurodegeneration. Cell Death & Disease. 2016. ↩︎
Khan MA, et al. Targeting ferritinophagy for neuroprotection. Autophagy. 2019. ↩︎
Gomez A, et al. NCOA4-mediated ferritinophagy in neuronal survival. Cell Death & Disease. 2022. ↩︎
Chen Q, et al. Iron metabolism and ferroptosis in Alzheimer's disease. Frontiers in Neuroscience. 2020. ↩︎
Baksi S, Singh N. Ferritin and neurotoxicity: implications for Parkinson's disease. Molecular Neurobiology. 2017. ↩︎
Angelova M, et al. Iron and ferritin in neurodegenerative diseases. Neurobiology of Disease. 2019. ↩︎ ↩︎
Chio A, et al. Iron accumulation in ALS: cause or consequence?. Journal of Neurology Neurosurgery & Psychiatry. 2019. ↩︎
Zecca L, Youdim MB. Iron, brain ageing and neurodegenerative disorders. Nature Reviews Neuroscience. 2004. ↩︎
Sawicka M, et al. Therapeutic targeting of iron accumulation in neurodegeneration. Molecular Therapy. 2024. ↩︎
Orriols M, et al. Ferritin heavy chain as therapeutic target in neurodegeneration. Trends in Pharmacological Sciences. 2019. ↩︎
Connor JR, Snyder BS. Iron regulation in the aging brain. Journal of Neural Transmission Supplement. 1992. ↩︎